Mycobiome

The fungal component of the human microbiome, comprising ~0.1-1% of the total gut microbial community by abundance but disproportionately active in immune signaling and cross-kingdom interactions. While bacterial communities dominate microbiome research, emerging evidence implicates the mycobiome in IBD, colorectal cancer, cardiovascular disease, MS, and metabolic syndrome — often through mechanisms distinct from bacterial dysbiosis.

Key Fungal Genera

Candida

  • Most abundant and best-studied gut fungus; C. albicans is the dominant species.
  • Enriched in obesity (contributes to elevated intestinal free fatty acids), T2DM, coronary artery disease, and heart failure [1].
  • In colon cancer, Candida-dominant tumors show reduced survival via IL-22, TP53, and CD44 pathways [2].
  • Capable of yeast-to-hyphal transition, forming biofilms and invading epithelium when immune surveillance is compromised.

Saccharomyces

  • S. cerevisiae is commensal; S. boulardii is used as a probiotic.
  • Enriched in some cardiometabolic diseases; S. boulardii supplementation failed to improve cardiac function in the GutHeart trial.
  • Saccharomycetes-dominant GI cancers show distinct patterns from Candida-dominant ones.

Malassezia

  • Lipophilic yeast; primarily skin-associated but detected in gut.
  • Significantly enriched in hypertension cohorts, positively correlated with immunoglobulin light chains [3].
  • M. restricta increased in obesity; Malassezia spp. enriched in pancreatic ductal adenocarcinoma (PDAC), where antifungal therapy shows therapeutic promise.

Aspergillus

  • Environmental mold; A. fumigatus is a major opportunistic pathogen.
  • Produces siderophores (TAFC, ferricrocin) for iron acquisition — detectable in urine as infection biomarkers [4].
  • A. dublinensis cell wall components induce islet-resident macrophage infiltration in diabetes models.

Cross-Kingdom Interactions

The mycobiome does not exist in isolation. Fungi and bacteria interact through:

  • Competition for nutrients: Bacteria and fungi compete for iron, carbon sources, and mucosal adhesion sites.
  • Mutual inhibition: Bacterial SCFAs lower pH, suppressing fungal overgrowth; antibiotic-induced bacterial depletion triggers Candida bloom.
  • Immune co-stimulation: Fungal beta-glucan (Dectin-1 ligand) and bacterial LPS (TLR4 ligand) synergistically activate innate immunity.
  • Biofilm cooperation: Mixed bacterial-fungal biofilms are more resistant to antimicrobials than single-kingdom biofilms.

Disease Associations

  • IBD: Increased Candida, decreased Saccharomyces; anti-S. cerevisiae antibodies (ASCA) are a diagnostic marker for Crohn's disease.
  • CRC: Intratumoral mycobiome detectable; oral fungi can reach the colon within 30 minutes via the sphincter of Oddi [2].
  • CVD/Hypertension: Malassezia and Candida enrichment; Mortierella appears protective in normotensive populations [1].
  • MS: Altered fungal diversity; cross-kingdom shifts under dietary intervention.

Metal Connections

  • Candida biosorption: C. albicans can biosorb heavy metals (Cd, Pb, Cu), potentially sequestering metals in the gut lumen but also shifting competitive dynamics with metal-sensitive bacteria.
  • Aspergillus siderophores: Iron-chelating metallophores (TAFC, ferricrocin, coprogen) are virulence factors that compete with host nutritional immunity for iron.
  • Metal-driven fungal bloom: Heavy metal-induced bacterial dysbiosis (loss of SCFA producers and pH control) creates conditions permissive for fungal overgrowth, paralleling antibiotic-induced candidiasis.

See Also

References (4)

  1. . wei 2025 gut mycobiome cardiometabolic disease
  2. . ding 2025 mycobiome human cancer mechanisms therapeutics
  3. . zou 2022 mycobiome dysbiosis hypertension light chains
  4. . patil 2021 infection metallomics critical care